GILD Long Put Strategy
GILD (Gilead Sciences, Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NASDAQ.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD (Gilead Sciences, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $165.19B, a trailing P/E of 17.93, a beta of 0.33 versus the broader market, a 52-week range of 97.86-157.29, average daily share volume of 6.2M, a public-listing history dating back to 1992, approximately 18K full-time employees. These structural characteristics shape how GILD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.33 indicates GILD has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. GILD pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long put on GILD?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current GILD snapshot
As of May 15, 2026, spot at $129.79, ATM IV 27.45%, IV rank 26.50%, expected move 7.87%. The long put on GILD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long put structure on GILD specifically: GILD IV at 27.45% is on the cheap side of its 1-year range, which favors premium-buying structures like a GILD long put, with a market-implied 1-standard-deviation move of approximately 7.87% (roughly $10.21 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GILD expiries trade a higher absolute premium for lower per-day decay. Position sizing on GILD should anchor to the underlying notional of $129.79 per share and to the trader's directional view on GILD stock.
GILD long put setup
The GILD long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GILD near $129.79, the first option leg uses a $130.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GILD chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GILD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $130.00 | $3.83 |
GILD long put risk and reward
- Net Premium / Debit
- -$382.50
- Max Profit (per contract)
- $12,616.50
- Max Loss (per contract)
- -$382.50
- Breakeven(s)
- $126.18
- Risk / Reward Ratio
- 32.984
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
GILD long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on GILD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$12,616.50 |
| $28.71 | -77.9% | +$9,746.88 |
| $57.40 | -55.8% | +$6,877.26 |
| $86.10 | -33.7% | +$4,007.65 |
| $114.79 | -11.6% | +$1,138.03 |
| $143.49 | +10.6% | -$382.50 |
| $172.19 | +32.7% | -$382.50 |
| $200.88 | +54.8% | -$382.50 |
| $229.58 | +76.9% | -$382.50 |
| $258.28 | +99.0% | -$382.50 |
When traders use long put on GILD
Long puts on GILD hedge an existing long GILD stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying GILD exposure being hedged.
GILD thesis for this long put
The market-implied 1-standard-deviation range for GILD extends from approximately $119.58 on the downside to $140.00 on the upside. A GILD long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long GILD position with one put per 100 shares held. Current GILD IV rank near 26.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on GILD at 27.45%. As a Healthcare name, GILD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GILD-specific events.
GILD long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GILD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GILD alongside the broader basket even when GILD-specific fundamentals are unchanged. Long-premium structures like a long put on GILD are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current GILD chain quotes before placing a trade.
Frequently asked questions
- What is a long put on GILD?
- A long put on GILD is the long put strategy applied to GILD (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With GILD stock trading near $129.79, the strikes shown on this page are snapped to the nearest listed GILD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are GILD long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the GILD long put priced from the end-of-day chain at a 30-day expiry (ATM IV 27.45%), the computed maximum profit is $12,616.50 per contract and the computed maximum loss is -$382.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GILD long put?
- The breakeven for the GILD long put priced on this page is roughly $126.18 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GILD market-implied 1-standard-deviation expected move is approximately 7.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on GILD?
- Long puts on GILD hedge an existing long GILD stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying GILD exposure being hedged.
- How does current GILD implied volatility affect this long put?
- GILD ATM IV is at 27.45% with IV rank near 26.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.